Table 4.
PBMCs proinflammatory, anti-inflammatory cytokine production and Foxp3-expressing T cells.
| Healthy controls (n = 13) | Placebo (n = 9) | Polymerized-type I collagen (n = 10) | ||||
|---|---|---|---|---|---|---|
| Baseline | 3 months | 6 months | 3 months | 6 months | ||
| CD4+/CD14−/IL-1β+(%); mean ± SD | 1.1 ± 0.3 | 1.8 ± 0.3 | 3.5 ± 1.9 | 2.6 ± 0.6 | 1.1 ± 0.2 | 1.8 ± 0.4 |
| Median | 0.9 | 1.3 | 2.0 | 2.1 | 1.1 | 1.5 |
| Range | (0.0–3.4) | (0.2–4.8) | (1.0–14.5) | (1.6–6.7) | (0.1–2.0) | (1.0–4.2) |
| CD4−/CD14+/IL-1β+(%); mean ± SD | 3.97 ± 0.7 | 4.9 ± 1.5 | 4.8 ± 1.3 | 8.5 ± 2.4 | 5.3 ± 1.0 | 3.3 ± 0.6* |
| Median | 3.7 | 2.4 | 3.9 | 6.9 | 5.8 | 3.1 |
| Range | (0.8–8.0) | (0.2–18.1) | (0.8–12.8) | (1.5–18.7) | (0.6–8.1) | (0.8–6.1) |
| CD4+/CD14+/IL-1β+(%); mean ± SD | 0.9 ± 0.3 | 0.8 ± 0.4 | 1.0 ± 0.3 | 2.9 ± 2.0 | 1.1 ± 0.4 | 1.0 ± 0.3 |
| Median | 0.8 | 0.7 | 0.6 | 2.1 | 0.7 | 0.8 |
| Range | (0.1–2.1) | (0.1–3.7) | (0.3–2.5) | (1.0–6.6) | (0.2–3.7) | (0.1–2.5) |
| CD4+/CD14−/TNF-α+(%); mean ± SD | 0.6 ± 0.1 | 1.7 ± 0.4 | 1.3 ± 0.4 | 2.3 ± 0.6 | 2.2 ± 0.7 | 1.2 ± 0.3 |
| Median | 0.6 | 1.5 | 1.0 | 1.5 | 1.5 | 1.3 |
| Range | (0.0–1.9) | (0.2–4.5) | (0.2–2.7) | (0.9–5.6) | (0.5–5.5) | (0.3–2.7) |
| CD4−/CD14+/TNF-α+(%); mean ± SD | 3.8 ± 0.7 | 4.7 ± 1.2 | 7.5 ± 2.3 | 5.6 ± 1.2 | 3.6 ± 0.9 | 3.5 ± 0.8 |
| Median | 4.1 | 2.4 | 6.9 | 5.3 | 3.4 | 2.7 |
| Range | (0.6–9.5) | (0.2–17.2) | (0.3–17.2) | (1.4–9.7) | (0.7–7.2) | (0.7–8.1) |
| CD4+/CD14+/TNF-α+(%); mean ± SD | 0.8 ± 0.2 | 0.7 ± 0.2 | 1.1 ± 0.6 | 1.2 ± 0.2 | 1.5 ± 0.5 | 0.9 ± 0.2 |
| Median | 0.7 | 0.5 | 0.3 | 1.1 | 1.3 | 1.0 |
| Range | (0.1–2.1) | (0.1–2.5) | (0.2–4.6) | (0.4–2.1) | (0.3–3.7) | (0.1–2.0) |
| CD4+/CD14−/IL-10+(%); mean ± SD | 2.3 ± 0.9 | 2.4 ± 0.5 | 1.4 ± 0.4 | 1.9 ± 0.5 | 2.7 ± 0.9 | 2.5 ± 0.5 |
| Median | 2.3 | 1.5 | 0.9 | 1.4 | 1.5 | 2.5 |
| Range | (0.2–4.6) | (0.3–7.1) | (0.2–3.0) | (0.2–3.8) | (0.2–7.6) | (0.4–4.5) |
| CD4−/CD14+/IL-10+(%); mean ± SD | 9.2 ± 1.1 | 5.0 ± 1.3 | 3.3 ± 0.8 | 3.8 ± 0.9 | 3.9 ± 1.1 | 15.2 ± 3.3* |
| Median | 8.9 | 2.4 | 3.5 | 3.9 | 3.5 | 14.7 |
| Range | (3.2–10.2) | (0.2–19.4) | (0.3–6.1) | (0.7–7.5) | (0.8–10.2) | (4.0–30.3) |
| CD4+/CD14+/IL-10+(%); mean ± SD | 1.2 ± 0.3 | 0.9 ± 0.4 | 0.6 ± 0.2 | 1.0 ± 0.3 | 0.5 ± 0.1 | 1.2 ± 0.1 |
| Median | 1.1 | 0.4 | 0.5 | 0.6 | 0.4 | 1.2 |
| Range | (0.2–1.6) | (0.1–6.7) | (0.0–1.6) | (0.1–2.6) | (0.1–0.8) | (0.5–1.7) |
| CD4+/CD14−/Foxp3+(%); mean ± SD | 3.8 ± 0.5 | 2.5 ± 0.8 | 2.2 ± 0.5 | 2.0 ± 0.3 | 2.5 ± 0.6 | 3.3 ± 0.3* |
| Median | 3.5 | 1.5 | 2.0 | 2.0 | 1.9 | 3.1 |
| Range | (2.1–8.8) | (0.1–14.2) | (0.5–4.3) | (0.8–3.2) | (1.1–5.6) | (2.2–4.7) |
| CD8+/IL-1β+(%); mean ± SD | 3.1 ± 1.1 | 2.5 ± 0.8 | 4.9 ± 1.5 | 1.4 ± 0.4 | 2.3 ± 0.5 | |
| Median | 1.0 | 1.7 | 3.6 | 1.3 | 2.4 | |
| Range | (0.2–15.0) | (0.7–8.4) | (1.6–14.5) | (0.1–3.0) | (0.7–4.5) | |
| CD8+/TNF-α+(%); mean ± SD | 2.9 ± 0.7 | 2.1 ± 0.8 | 3.4 ± 1.5 | 1.4 ± 0.3 | 1.8 ± 0.4 | |
| Median | 1.9 | 0.8 | 0.8 | 1.2 | 1.5 | |
| Range | (0.2–11.8) | (0.0–7.6) | (0.2–11.3) | (0.1–2.7) | (0.6–3.5) | |
| CD8+/IFN-γ+(%); mean ± SD | 7.4 ± 1.5 | 6.7 ± 1.6 | 3.7 ± 0.6 | 4.4 ± 0.9 | 3.3 ± 0.7 | |
| Median | 4.6 | 5.6 | 3.0 | 3.8 | 3.0 | |
| Range | (0.5–18.8) | (1.2–17.4) | (2.2–6.8) | (0.8–8.1) | (1.1–6.9) | |
| CD8+/CD28−/Foxp3+(%); mean ± SD | 2.9 ± 0.6 | 6.9 ± 1.3 | 4.3 ± 0.8 | 4.7 ± 1.0 | 6.9 ± 1.1* | 6.5 ± 1.0 |
| Median | 3.1 | 4.0 | 4.5 | 3.9 | 6.9 | 6.4 |
| Range | (0.2–6.2) | (0.5–18.0) | (1.3–9.3) | (1.3–9.9) | (2.4–9.6) | (3.1–11.4) |